These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31525463)

  • 21. Folate-Modified Liposomes Loaded with Telmisartan Enhance Anti-Atherosclerotic Potency for Advanced Atherosclerosis in ApoE
    Fang D; Jin Q; Jin Z; Wang F; Huang L; Yang Y; He Z; Liu Y; Jiang C; Wu J; Song X
    J Biomed Nanotechnol; 2019 Jan; 15(1):42-61. PubMed ID: 30480514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Cardiovascular Disease Risk Factor Burden With Progression of Coronary Atherosclerosis Assessed by Serial Coronary Computed Tomographic Angiography.
    Han D; Berman DS; Miller RJH; Andreini D; Budoff MJ; Cademartiri F; Chinnaiyan K; Choi JH; Conte E; Marques H; de Araújo Gonçalves P; Gottlieb I; Hadamitzky M; Leipsic J; Maffei E; Pontone G; Shin S; Kim YJ; Lee BK; Chun EJ; Sung JM; Lee SE; Virmani R; Samady H; Stone P; Narula J; Bax JJ; Shaw LJ; Lin FY; Min JK; Chang HJ
    JAMA Netw Open; 2020 Jul; 3(7):e2011444. PubMed ID: 32706382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
    Cannon CP; Khan I; Klimchak AC; Sanchez RJ; Sasiela WJ; Massaro JM; D'Agostino RB; Reynolds MR
    Am Heart J; 2019 Oct; 216():30-41. PubMed ID: 31386936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-inflammatory cytokine IL10 loaded cRGD liposomes for the targeted treatment of atherosclerosis.
    Li J; Ding F; Qian X; Sun J; Ge Z; Yang L; Cheng Z
    J Microencapsul; 2021 Sep; 38(6):357-364. PubMed ID: 33048003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline Risk Increases: A Meta-Regression Analysis.
    Nudy M; Cooper J; Ghahramani M; Ruzieh M; Mandrola J; Foy AJ
    Am J Med; 2020 Sep; 133(9):1056-1064. PubMed ID: 32445718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of atherosclerosis by traditional Chinese medicine: Questions and quandaries.
    Wang C; Niimi M; Watanabe T; Wang Y; Liang J; Fan J
    Atherosclerosis; 2018 Oct; 277():136-144. PubMed ID: 30212682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Smoking and atherosclerotic cardiovascular disease in women with lower levels of serum cholesterol.
    Jee SH; Park J; Jo I; Lee J; Yun S; Yun JE; Jang Y
    Atherosclerosis; 2007 Feb; 190(2):306-12. PubMed ID: 16677653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ideal cardiovascular health and incidence of atherosclerotic cardiovascular disease among Chinese adults: the China-PAR project.
    Han C; Liu F; Yang X; Chen J; Li J; Cao J; Li Y; Shen C; Yu L; Liu Z; Wu X; Zhao L; Hu D; Lu X; Wu X; Gu D
    Sci China Life Sci; 2018 May; 61(5):504-514. PubMed ID: 29721777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
    Anderson JL; Knowlton KU; May HT; Bair TL; Armstrong SO; Lappé DL; Muhlestein JB
    J Clin Lipidol; 2018; 12(4):1008-1018.e1. PubMed ID: 29703626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
    Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
    Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.
    Sandesara PB; Virani SS; Fazio S; Shapiro MD
    Endocr Rev; 2019 Apr; 40(2):537-557. PubMed ID: 30312399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea.
    Kim S; Kim H; Kim E; Han S; Rane PP; Fox KM; Zhao Z; Qian Y; Suh HS
    Clin Ther; 2018 Jun; 40(6):940-951.e7. PubMed ID: 29735297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
    Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Three Atherosclerotic Cardiovascular Disease Risk Scores With and Without Coronary Calcium for Predicting Revascularization and Major Adverse Coronary Events in Symptomatic Patients Undergoing Positron Emission Tomography-Stress Testing.
    Anderson JL; Le VT; Min DB; Biswas S; Minder CM; McCubrey RO; Knight S; Horne BD; Mason S; Lappe DL; Muhlestein JB; Knowlton KU
    Am J Cardiol; 2020 Feb; 125(3):341-348. PubMed ID: 31806210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017.
    Okuyama H; Hamazaki T; Hama R; Ogushi Y; Kobayashi T; Ohara N; Uchino H
    Pharmacology; 2018; 101(3-4):184-218. PubMed ID: 29353277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.